For symptomatic relief of<unk> : * Octreotide (a somatostatin analogue which decreases the secretion of serotonin by the tumor and, secondarily, decreases the breakdown product of serotonin (5-HIAA)) * Telotristat ethyl (Xermelo) along with a somatostatin analogue in patients not responding to somatostatin analogue monotherapy. It is a tryptophan hydroxylase inhibitor and reduces the production of serotonin. * Peptide receptor radionuclide therapy (PRRT) with lutetium-177, yttrium-90 or indium-111 labeled to octreotate is highly effective * Methysergide maleate (antiserotonin agent but not used because of the serious side effect of retroperitoneal fibrosis) * Cyproheptadine (an antihistamine drug with antiserotonergic effects) Alternative treatment for qualifying patients: *Surgical resection of tumor and chemotherapy (5-FU and doxorubicin) *Endovascular, chemoembolization, targeted chemotherapy directly delivered to the liver through special catheters mixed with embolic beads (particles that block blood vessels), used for patients with liver metastases. Uncertainties Disease progression is difficult to ascertain because the disease can metastasize anywhere in the body and can be too small to identify with any current technology. Markers of the condition such as chromogranin-A are imperfect indicators of disease progression.
Carcinoid syndrome
Anaphylaxis
Carcinosis
Stress ulcer
Portal hypertension
Madarosis
Amyloidosis
Alcohol intolerance